Self-Assessment of amyotrophic lateral sclerosis functional rating scale on the patient’s smartphone proves to be non-inferior to clinic data capture

Competing Interest Statement

TM has received grants, personal fees, nonfinancial support and research support from ALS Pharma, Amylyx, Cytokinetics, Ferrer, Mitsubishi Tanabe, Sanofi, Orphazyme, and served on the advisory boards of Amylyx, Biogen, and ITF Pharma outside of the submitted work. TM and CM are founders and shareholders of the Ambulanzpartner Soziotechnologie APST GmbH, which makes the mobile application ALS App.TG has received personal fees from ITF Pharma and served on the advisory boards of Amylyx and ITF Pharma outside of the submitted work. SP has received speaker fees, nonfinancial support and research support from Biogen, Roche, ALS Pharma, Amylyx, Cytokinetics, Ferrer, ITF Pharma, and Sanofi and served on advisory boards of Amylyx, Biogen, Roche, Zambon and ITF Pharma outside of the submitted work. PW has served on advisory boards of Biogen, ITF Pharma and Novartis outside of the submitted work. RG has received grants, personal fees, nonfinancial support and research support from Biogen and served on the advisory boards of Biogen, Roche, and ITF Pharma outside of the submitted work. MV received travel expenses and nonfinancial support from ITF Pharma outside of the submitted work. AM has received personal fees, nonfinancial support, and research support from ITF Pharma and Zambon outside the submitted work. PK received consulting fees from Biogen. PL reports grants from the Bundesministerium fuer Bildung und Forschung and the Deutsche Forschungsgemeinschaft; consulting fees from AbbVie, Amylyx, Bial, Desitin, ITF Pharma, Novartis, Stadapharm, Raya Therapeutic, Woolsey Pharmaceuticals, and Zambon; and is coinventor on a patent for the use of fasudil in amyotrophic lateral sclerosis (EP 2825175 B1, US 9.980,972 B2), outside of the scope of the submitted work. The other authors declare no conflicts of interest.

Funding Statement

This work was supported by the Boris Canessa ALS Stiftung (Duesseldorf).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Medical Ethics Committee of Charite Universitaetsmedizin Berlin, Germany under number EA1/219/15. A signed patient information and informed consent form was obtained from all the participating patients.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes